HRP20040665B1 - Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment - Google Patents

Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment

Info

Publication number
HRP20040665B1
HRP20040665B1 HRP20040665A HRP20040665B1 HR P20040665 B1 HRP20040665 B1 HR P20040665B1 HR P20040665 A HRP20040665 A HR P20040665A HR P20040665 B1 HRP20040665 B1 HR P20040665B1
Authority
HR
Croatia
Prior art keywords
compounds
treatment
methods
compositions containing
fluoro substituted
Prior art date
Application number
Other languages
English (en)
Inventor
Carl Berthelette
Nicolas Lachance
Lianhai Li
Claudio Sturino
Zhaoyin Wang
Original Assignee
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Inc filed Critical Merck Frosst Canada Inc
Publication of HRP20040665A2 publication Critical patent/HRP20040665A2/hr
Publication of HRP20040665B1 publication Critical patent/HRP20040665B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
HR20040665 2002-01-24 2004-07-19 Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment HRP20040665B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35138402P 2002-01-24 2002-01-24
PCT/CA2003/000084 WO2003062200A2 (fr) 2002-01-24 2003-01-22 Cycloalkanoindoles a substitution fluor, compositions contenant de tels composes, et procedes de traitement

Publications (2)

Publication Number Publication Date
HRP20040665A2 HRP20040665A2 (en) 2005-04-30
HRP20040665B1 true HRP20040665B1 (en) 2012-11-30

Family

ID=27613492

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20040665 HRP20040665B1 (en) 2002-01-24 2004-07-19 Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment

Country Status (39)

Country Link
US (6) US20030158246A1 (fr)
EP (3) EP2045241B1 (fr)
JP (2) JP4008885B2 (fr)
KR (2) KR100859230B1 (fr)
CN (3) CN1902176A (fr)
AR (1) AR038136A1 (fr)
AT (1) ATE414690T1 (fr)
AU (1) AU2003202343B2 (fr)
BR (1) BR0307050A (fr)
CA (1) CA2471952C (fr)
CY (3) CY1108841T1 (fr)
DE (2) DE60324767D1 (fr)
DK (2) DK1470107T3 (fr)
DO (1) DOP2003000566A (fr)
EA (1) EA006134B1 (fr)
EC (1) ECSP045203A (fr)
EG (1) EG24978A (fr)
ES (2) ES2316717T3 (fr)
FR (1) FR09C0010I2 (fr)
GE (1) GEP20074078B (fr)
HR (1) HRP20040665B1 (fr)
IL (3) IL162825A0 (fr)
IS (2) IS2633B (fr)
JO (1) JO2481B1 (fr)
LU (1) LU91534I2 (fr)
MX (1) MXPA04007167A (fr)
MY (1) MY137040A (fr)
NL (1) NL300377I2 (fr)
NO (3) NO327322B1 (fr)
NZ (1) NZ533786A (fr)
PE (1) PE20030982A1 (fr)
PL (1) PL208527B1 (fr)
PT (2) PT1470107E (fr)
RS (2) RS20100338A (fr)
SI (2) SI2045241T1 (fr)
TW (1) TWI259080B (fr)
UA (1) UA75520C2 (fr)
WO (1) WO2003062200A2 (fr)
ZA (1) ZA200404999B (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7273883B2 (en) * 2000-09-14 2007-09-25 Allergan, Inc. Prostaglandin EP4 antagonist
US7217725B2 (en) * 2000-09-14 2007-05-15 Allergan, Inc. Prostaglandin D2 antagonist
AR038136A1 (es) * 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
AR041089A1 (es) * 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
WO2004104205A2 (fr) * 2003-05-16 2004-12-02 Merck & Co., Inc. Preparation enzymatique d'esters d'indole chiraux
CN1791577A (zh) * 2003-05-20 2006-06-21 麦克弗罗斯特加拿大有限公司 氟－甲基磺酰取代的环烷并吲哚和它们作为前列腺素d2拮抗剂的用途
ATE464048T1 (de) * 2003-08-07 2010-04-15 Merck Sharp & Dohme Behandlung von alzheimer-krankheit und verwandten zuständen
PE20050483A1 (es) 2003-10-31 2005-08-25 Arena Pharm Inc Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
US7019022B2 (en) * 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
JP4051398B2 (ja) 2004-03-11 2008-02-20 アクテリオン ファマシューティカルズ リミテッド テトラヒドロピリドインドール誘導体
TWI344954B (en) * 2004-04-02 2011-07-11 Merck Sharp & Dohme Asymmetric hydrogenation process
HN2005000795A (es) 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
WO2006052798A2 (fr) * 2004-11-08 2006-05-18 Merck & Co., Inc. Methode de traitement des rougeurs pathologiques
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
WO2006068162A1 (fr) * 2004-12-24 2006-06-29 Shionogi & Co., Ltd. Agent thérapeutique pour le traitement de la bronchopneumopathie chronique obstructive
KR101329903B1 (ko) * 2004-12-27 2013-11-14 액테리온 파마슈티칼 리미티드 Ｃｒｔｈ2 수용체 길항제로서의2,3,4,9-테트라하이드로-1ｈ-카르바졸유도체
AU2006214018A1 (en) * 2005-02-17 2006-08-24 Merck Sharp & Dohme Corp. Method of treating atherosclerosis, dyslipidemias and related conditions
CN101160125A (zh) * 2005-04-13 2008-04-09 默克公司 烟酸受体激动剂、含有这样化合物的组合物和治疗方法
WO2007010965A1 (fr) 2005-07-22 2007-01-25 Shionogi & Co., Ltd. Dérivé d'azaindole ayant une activité antagoniste vis-à-vis du récepteur de la pgd2
JP5072594B2 (ja) 2005-07-22 2012-11-14 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するインドール誘導体
EP1932839A4 (fr) 2005-09-06 2014-09-10 Shionogi & Co Dérivé d acide indolécarboxylate ayant une activité à effet antagoniste du récepteur pgd2
WO2007149312A2 (fr) 2006-06-16 2007-12-27 The Trustees Of The University Of Pennsylvania Procédés et compositions destinés à inhiber ou à réduire la perte des cheveux, l'acné, la rosacée, le cancer de la prostate, et la bph
KR101411820B1 (ko) 2006-08-07 2014-06-24 액테리온 파마슈티칼 리미티드 (3-아미노-1,2,3,4-테트라하이드로-9ｈ-카르바졸-9-일)-아세트산 유도체
EP2114154B1 (fr) * 2007-02-08 2013-08-28 Merck Sharp & Dohme Corp. Procédé de traitement de l'athérosclérose, des dyslipidémies et d'états pathologiques apparentés
US20090076117A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched laropiprant
WO2010008864A2 (fr) 2008-06-24 2010-01-21 Amira Pharmaceuticals, Inc. Antagonistes de cycloalcane[b]indole de récepteurs de prostaglandine d2
US8507473B2 (en) 2008-09-11 2013-08-13 Arena Pharmaceuticals, Inc. 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders
MX2011003166A (es) * 2008-09-25 2011-04-27 Merck Frosst Canada Ltd Derivados de sulfonilurea beta-carbolina como antagonistas del receptor ep4.
GB2463788B (en) * 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
US9180114B2 (en) * 2008-11-26 2015-11-10 President And Fellows Of Harvard College Neurodegenerative diseases and methods of modeling
US8882678B2 (en) * 2009-03-13 2014-11-11 Atrium Medical Corporation Pleural drainage system and method of use
JP5291265B2 (ja) 2010-03-22 2013-09-18 アクテリオン ファーマシューティカルズ リミテッド ３−（ヘテロアリール−アミノ）−１，２，３，４−テトラヒドロ−９ｈ−カルバゾール誘導体及びプロスタグランジンｄ２受容体調節剤としてのそれらの使用
JP5964945B2 (ja) 2011-04-14 2016-08-03 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ ７−（ヘテロアリ−ル−アミノ）−６，７，８，９−テトラヒドロピリド［１，２−ａ］インド−ル酢酸誘導体及びプロスタグランジンＤ２受容体調節剤としてのそれらの使用
JP5841361B2 (ja) * 2011-06-29 2016-01-13 壽製薬株式会社 三環性化合物及びそれを含有する医薬組成物
AR088377A1 (es) * 2011-10-20 2014-05-28 Siena Biotech Spa Proceso para la preparacion de 6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida y compuestos intermedios de esta
CN102659664B (zh) * 2012-03-28 2015-01-21 中国计量学院 合成分离拉洛皮兰及其类似物的方法
FR3000395A1 (fr) * 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et d'oxymetazoline pour le traitement de la rosacee
FR3000399B1 (fr) * 2012-12-31 2015-03-27 Galderma Res & Dev Utilisation topique du laropiprant pour le traitement de la rosacee
PT3119779T (pt) 2014-03-17 2018-10-19 Idorsia Pharmaceuticals Ltd Derivados de ácido azaindol acético e sua utilização como modeladores de recetor d2 de prostaglandina
ES2699379T3 (es) 2014-03-18 2019-02-11 Idorsia Pharmaceuticals Ltd Derivados de ácido azaindol acético y su uso como moduladores del receptor de prostaglandina D2
US20180021302A1 (en) 2015-02-13 2018-01-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus
US10351560B2 (en) 2015-09-15 2019-07-16 Idorsia Pharmaceuticals Ltd Crystalline forms
CN111886315B (zh) 2018-03-19 2023-06-30 三井化学株式会社 显示元件用密封材及其固化物、有机el元件用框密封材以及有机el元件用面密封材

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3535326A (en) * 1967-03-06 1970-10-20 Sumitomo Chemical Co Certain tetrahydro carboline derivatives
BE787444A (fr) * 1971-08-13 1973-02-12 Hoffmann La Roche Composes polycycliques
US4009181A (en) * 1973-01-22 1977-02-22 Hoffmann-La Roche Inc. Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
US4057559A (en) * 1973-10-01 1977-11-08 American Home Products Corporation Carbazole acetic acid derivatives
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5021447A (en) * 1986-01-23 1991-06-04 Merck Frosst Canada, Inc. Tetrahydrocarbazole 1-alkanoic acids and pharmaecutical compositions
ES2038653T3 (es) 1986-01-23 1993-08-01 Merck Frosst Canada Inc. Acidos 1-alcanoicos tetrahidrocarbazol.
US4808608A (en) * 1986-01-23 1989-02-28 Merck & Co., Inc. Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
US4940719A (en) * 1986-03-27 1990-07-10 Merck Frosst Canada, Inc. Tetrahydrocarbazole esters, pharmaceutical compositions and use
US4775680A (en) * 1987-07-21 1988-10-04 Merck & Co., Inc. Cyclohept[b]indolealkanoic acids, pharmaceutical compositions and use
US5221678A (en) 1990-07-26 1993-06-22 Merck Frosst Canada, Inc. (quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
GB9101375D0 (en) 1991-01-22 1991-03-06 Erba Carlo Spa N-imidazolyl derivatives of substituted tetrahydrocarbazole and cyclohepht(b)indole
WO1995015973A1 (fr) 1993-12-06 1995-06-15 Cytel Corporation Peptidomimetiques cs-1, compositions et procedes pour les utiliser
US5510332A (en) 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
WO1996001644A1 (fr) 1994-07-11 1996-01-25 Athena Neurosciences, Inc. Inhibiteurs de l'adhesion leucocytaire
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
WO1996031206A2 (fr) 1995-04-07 1996-10-10 Warner-Lambert Company Flavones et coumarines utilisees en tant qu'agents dans le traitement de l'atherosclerose
WO1996040781A1 (fr) 1995-06-07 1996-12-19 Tanabe Seiyaku Co., Ltd. INHIBITEURS PEPTIDIQUES CYCLIQUES D'ADHERENCE CELLULAIRE INDUITE PAR INTEGRINE β1 ET β¿2?
IL122332A0 (en) 1995-06-21 1998-04-05 Shionogi & Co Bicyclic amino derivatives and PGD2 antagonist containing the same
US6034057A (en) 1995-07-06 2000-03-07 Zeneca Limited Peptide inhibitors of fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
RU2161617C1 (ru) 1996-12-13 2001-01-10 Шионоги энд Ко. Лтд. Бензотиофенкарбоксамидные производные, содержащие их антагонисты pgd2, фармацевтическая композиция и лекарственное средство
ES2241283T3 (es) 1998-06-03 2005-10-16 SHIONOGI & CO., LTD. Remedios para el tratamiento del prurito que contienen antagonistas de pgd2.
US20010047027A1 (en) 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
US6410583B1 (en) * 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
AR038136A1 (es) * 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
US7019022B2 (en) * 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives

Also Published As

Publication number Publication date
JP4008885B2 (ja) 2007-11-14
MY137040A (en) 2008-12-31
NO20071193L (no) 2004-08-24
RS20100338A (en) 2011-06-30
CY1113330T1 (el) 2016-06-22
CY2009004I2 (el) 2009-11-04
IS2633B (is) 2010-06-15
NZ533786A (en) 2006-11-30
AR038136A1 (es) 2004-12-29
PE20030982A1 (es) 2003-11-19
DE122009000022I1 (de) 2009-08-06
FR09C0010I2 (fr) 2009-12-18
IS7329A (is) 2004-06-21
IS8887A (is) 2010-03-01
EP1470107B1 (fr) 2008-11-19
CY2009004I1 (el) 2009-11-04
MXPA04007167A (es) 2004-10-29
NO327322B1 (no) 2009-06-08
LU91534I2 (fr) 2009-04-27
US20030158246A1 (en) 2003-08-21
NO2009013I2 (no) 2012-08-27
IL162825A (en) 2010-12-30
CN1902176A (zh) 2007-01-24
GEP20074078B (en) 2007-03-26
EP2295409B1 (fr) 2014-07-02
DOP2003000566A (es) 2003-09-15
FR09C0010I1 (fr) 2009-04-17
US7317036B2 (en) 2008-01-08
US7618994B2 (en) 2009-11-17
CA2471952C (fr) 2008-04-01
PT2045241E (pt) 2012-09-26
US20080033028A1 (en) 2008-02-07
US20120115921A1 (en) 2012-05-10
US20050124680A1 (en) 2005-06-09
UA75520C2 (en) 2006-04-17
CN101851191A (zh) 2010-10-06
KR100859230B1 (ko) 2008-09-18
ES2391747T3 (es) 2012-11-29
PT1470107E (pt) 2009-01-30
EG24978A (en) 2011-04-03
ATE414690T1 (de) 2008-12-15
JP2005518413A (ja) 2005-06-23
EP2045241A1 (fr) 2009-04-08
NO20043536L (no) 2004-08-24
RS62404A (en) 2006-12-15
EA200400971A1 (ru) 2004-12-30
US20060069148A1 (en) 2006-03-30
SI2045241T1 (sl) 2012-11-30
NL300377I2 (nl) 2009-08-03
PL370427A1 (en) 2005-05-30
DE60324767D1 (de) 2009-01-02
IL162825A0 (en) 2005-11-20
ES2316717T3 (es) 2009-04-16
DK1470107T3 (da) 2009-03-09
CA2471952A1 (fr) 2003-07-31
HRP20040665A2 (en) 2005-04-30
PL208527B1 (pl) 2011-05-31
AU2003202343B2 (en) 2007-07-12
US20100081696A1 (en) 2010-04-01
JO2481B1 (en) 2009-01-20
EP2295409A1 (fr) 2011-03-16
EP2045241B1 (fr) 2012-07-04
JP2007186521A (ja) 2007-07-26
NO2009013I1 (no) 2009-06-29
NL300377I1 (nl) 2009-05-06
AU2003202343C1 (en) 2003-09-02
IL188844A0 (en) 2009-02-11
SI1470107T1 (sl) 2009-04-30
CN101092388A (zh) 2007-12-26
DK2045241T3 (da) 2012-10-15
EP1470107A2 (fr) 2004-10-27
KR20070056166A (ko) 2007-05-31
TW200302090A (en) 2003-08-01
BR0307050A (pt) 2004-10-26
TWI259080B (en) 2006-08-01
KR20040075109A (ko) 2004-08-26
RS51672B (en) 2011-10-31
EA006134B1 (ru) 2005-10-27
ECSP045203A (es) 2004-09-28
CY1108841T1 (el) 2011-04-06
WO2003062200A2 (fr) 2003-07-31
ZA200404999B (en) 2006-05-31
WO2003062200A3 (fr) 2003-12-04

Similar Documents

Publication Publication Date Title
HRP20040665B1 (en) Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment
EP1626717A4 (fr) Benzimidazoles, compositions contenant lesdits composes et methodes d'utilisation
HK1083835A1 (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
HK1081957A1 (en) Benzopyranone compounds, compositions thereof, and methods of treatment therewith
GB2393202B (en) Methods of well treatment
HK1152474A1 (en) Methods and compositions for the prevention and treatment of sepsis
EP1680111A4 (fr) Procedes d'utilisation et compositions comprenant des composes immunomodulaires pour traiter, modifier et gerer la douleur
EP1560817A4 (fr) Methodes et compositions a base de nouveaux composes de triazine
HK1086485A1 (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
IL164266A0 (en) Treatment of gastroparesis
EP1569915A4 (fr) Urees spirocycliques, compositions les contenant et procedes d'utilisation
EP1651231A4 (fr) Cycloalcanes diphenyl-substitutes, compositions contenant ces composes, et procedes d'utilisation
EP1667999A4 (fr) Composes benzopyranone, compositions a partir de ces composes et technique de traitement utilisant ces compositions
EP1551388A4 (fr) Composes utiles dans le traitement du cancer, compositions et procedes correspondants
IL175369A0 (en) Novel compound, corresponding compositions, preparation and/or treatment methods
ZA200503240B (en) Methods of using and compositions comprising immunodulatory compounds for treatment, modification and management of pain
EP1575497A4 (fr) Nouvelle composition et nouveaux procedes pour le traitement du psoriasis
GB0324523D0 (en) Compositions and methods of treatment
GB0306309D0 (en) Method of treatment
GB0302572D0 (en) Method of treatment
PL352750A1 (en) Novel isoindoloindolone compounds, method of obtaining them and pharamcological composition containing such compounds
AU2003225563A8 (en) Compositions and methods for treatment of osteoarthritis
GB0217493D0 (en) Novel methods of treatment
GB0208897D0 (en) New method of treatment
AU2003240174A8 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20140121

Year of fee payment: 12

PBON Lapse due to non-payment of renewal fee

Effective date: 20150122